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Abstract To investigate the expression levels of
CXCL10 and CXCR3 in tumors from breast cancer patients
randomized to adjuvant tamoxifen treatment or no endo-
crine treatment, in order to further study the connection to
prognosis and prediction of tamoxifen treatment outcome.
Immunohistochemistry on tissue microarrays from 912
breast cancer patients randomized to tamoxifen or no
endocrine treatment. CXCR3 status was found to be a
prognostic tool in predicting distant recurrence, as well as
reduced breast cancer-specific survival. In patients with
estrogen receptor (ER)-positive tumors, tumors with strong
CXCL10 levels had improved effect of tamoxifen treat-
ment in terms of local recurrence-free survival [risk ratio
(RR) 0.46 (95 % CI 0.25–0.85, P = 0.01)] compared with
patients with tumors expressing weak CXCL10 expression.
Further, patients with ER-positive tumors with strong
CXCR3 expression had an improved effect of tamoxifen in
terms of breast cancer-specific survival [RR 0.34 (95 % CI
0.19–0.62, P \ 0.001)] compared with the group with
weak CXCR3 levels [RR 1.33 (95 % CI 0.38–4.79,
P = 0.65)]. We show here for the first time that CXCL10
and CXCR3 expression are both predictors of favorable
outcome in patients treated with tamoxifen.
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Introduction
Breast cancer is the most common form of cancer among
women. There is increasing evidence suggesting the rele-
vance of interactions between microenvironment and
mammary epithelial for proliferation, differentiation, sur-
vival, and invasion. The mechanisms behind these inter-
actions are to a large extent unknown, but inflammatory
cells are suggested to play an important role in breast
cancer. This work focuses on the chemokine, C–X–C motif
ligand 10 (CXCL10), also known as c-interferon-induced
protein of 10 kDa (IP 10). CXCL10s ability to recruit
T-cells is well known [1–5], and its role in cancer is
established [6–10]. CXCL10 is under the positive regula-
tion of interferon-a and -c [10, 11], interleukin-10 [12],
interleukin-1a, and tumor necrosis factor (TNF)-a [13]. In
a murine model, mice injected with CXCL10-expressing
tumor cells, CXCL10 prevented the formation of new
tumors, and mediated the regression of existing ones [14].
The primary receptor for CXCL10 is C–X–C motif
receptor 3 (CXCR3). CXCR3 has two reported isoforms.
CXCR3-A, the originally discovered isoform, mediates
chemotaxis of immune and cancer cells, as well as prolif-
erative signaling and promotion of angiogenesis [15–17].
CXCR3-B inhibits cell motility, reduces proliferative sig-
naling and inhibits angiogenesis [15–18]. Increase of total
CXCR3 has been observed in breast cancer, but no analysis
of CXCR3-A and CXCR3-B ratio has been conducted [8,
15, 16].
The relevance and function of CXCL10 and CXCR3 in
terms of prognosis and breast cancer treatment prediction is
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poorly understood. Estrogen has been reported to reduce
CXCL10 expression [19] and tamoxifen may enhance the
immune response [1, 2, 20, 21]. The purpose of this study
was to investigate the expression levels of CXCL10 and
CXCR3 in tumors from breast cancer patients randomized
to adjuvant tamoxifen treatment or no endocrine treatment,
to further study the connection to prognosis and prediction
of tamoxifen treatment outcome in low risk and low stage
patients.
Materials and methods
This study was designed and presented with regard to the
reporting recommendations for tumor marker prognostic
studies (REMARK) guidelines [22].
Patients
This retrospective cohort study was conducted using tumor
material from a randomized tamoxifen trial conducted in
1976–1990 in Stockholm Sweden composed of 1,780
patients. Results and details of the trial were previously
described [23]. All patients were postmenopausal with
tumors B30 mm and were negative for axillary lymph node
involvement (N0). The patients received either breast
conserving surgery followed by radiation treatment with a
dose of 50 Gy with 2 Gy per fraction 5 days weekly, for
about 5 weeks, or radical mastectomy. After surgery,
patients were randomized to tamoxifen 40 mg daily or no
endocrine treatment. After 2 years of tamoxifen treatment,
most disease-free patients were randomized to tamoxifen
for an additional 3 years or no further therapy. Tumor
material from 912 women was available for the current
investigation. The mean follow-up period for patients in the
study was 18 years. The trial design and protocol was
approved by the Research Ethics Committee at the Karo-
linska Institute (dnr 97–451, with amendments) [23]. In
order to conduct tissue microarray analysis, a pathologist
chose representative parts of the tumors. Three cores per
patient with a diameter of 0.8 mm were chosen and
transferred to a paraffin block using a manual arrayer
(Beecher Instruments, Sun Prairie, WI). From the sample
blocks sections were cut and placed on slides, forming the
basis of the tissue microarray. A flow chart of patients
included in the initial tamoxifen trial and further included
in the current analysis is shown in Fig. 1. Estrogen receptor
(ER) and progesterone receptor (PgR) status were deter-
mined with cut-off levels at 10 % of positively stained
tumor cell nuclei, cytosol measurements were used in the
case of missing immunohistochemical data, with a cut-off
of 0.05 fmol/lg DNA [23]. HER2 expression score 0–3
was previously described [24].
Immunostaining for CXCL10 and CXCR3 expression
Tissue microarray sample slides were heated to 60 C for
12 h and stored at -70 C. Following thawing, the sample
slides were deparaffinized with Tissue Clear (HistoLab,
Go¨teborg, Sweden). The sample slides were washed with
decreasing concentrations of ethanol followed by water,
after which they were placed in DIVA-buffer (BioCare,
Concord, CA) inside a decloaking chamber (BioCare),
heated to 120 C, cooled to 90 C and then left in room
temperature. The sample slides were washed with PBS
containing 0.1 % bovine serum albumin (BSA) and Protein
Block (Spring Bioscience, Pleasanton, CA). Primary
monoclonal anti-CXCR3 antibody [2Ar1] at 500 ng/ml
(Abcam, Cambridge, UK), primary polyclonal rabbit anti-
CXCL10 antibody at 111 ng/ml (ab9807, Abcam) or control
IgG mouse antibody at 500 or 111 ng/ml (DAKO, Glostrup,
Denmark) were added and the sample slides were incubated
overnight at 4 C. Envision secondary anti-mouse antibody
conjugated to HRP (DAKO) was added, thereafter the
sample slides were incubated in 3,30-diaminobenzidine
tetrahydrochloride (DAB) with hydrogen peroxide and
counterstained with hematoxylin (BioRad, Hercules, CA),
rehydrated and fixated with Mount-X (HistoLab) mounting
Fig. 1 Study design and patient flow chart
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solution. Grading was done using a Leica LB30T microscope
(Leica Microsystems, Wetzlar, Germany). Sample scoring
was done without evaluators’ knowledge of clinical or
pathological data for patients, using a 0–3 scaling system, -
indicating no staining, ? indicating weak expression, ??
indicating moderate expression, and ??? indicating a
strong expression. Only tumor cells were analyzed. Two
individual evaluators judged all slides independently. Rep-
resentative slides for each intensity were photographed using
an Axio Lab A1 microscope with an AxioCam ICc5 camera
(Zeiss, Oberkochen, Germany), all images were acquired
using image acquire software Zen 2012 blue edition (Zeiss).
Statistical analysis
The relationships between grouped variables were ana-
lyzed using Spearman’s rank order correlation. To com-
pensate for multiple testing P \ 0.01 was set as significant.
The survival curves were produced according to the lifet-
able method described by Kaplan and Meier and differ-
ences between groups were evaluated with log-rank tests.
Patients with missing data were excluded. Univariate and
multivariate analysis were conducted using Cox propor-
tional hazards regression and P \ 0.05 was considered
significant. End points used were breast cancer-specific
mortality, defined as when patients had a local or distant
recurrence or when so stated by the Swedish cause of death
registry. Local recurrence defined as a relapse on either
chest wall or in a regional lymph node or distant
recurrence, defined as the remaining metastatic events. The
statistical package Statistica 10.0 (StatSoft Scandinavia,
Uppsala, Sweden) was used for all calculations.
Results
CXCL10 and CXCR3 expression in relation to tumor
characteristics
Out of 912 patients, data for CXCL10 expression were
acquired from 793 cases. In our material, 51 (6 %) of the
patients showed no CXCL10 expression, 183 (23 %) weak
expression, 224 (28 %) moderate expression, and 335
(42 %) strong expression (Fig. 2). Data for CXCR3
expression were acquired from 735 cases and 29 (4 %)
patients showed no expression, 121 (17 %) weak expres-
sion, 282 (38 %) moderate expression, and 303 (41 %)
strong CXCR3 expression (Fig. 3). CXCR3 expression was
positively correlated with HER2 expression (P \ 0.001),
no correlation between CXCL10 and CXCR3 was found,
and no correlation between ER, PgR nor tumor size was
detected for CXCL10 or CXCR3 (Tables 1, 2).
CXCL10 and CXCR3 are predictive factors
of tamoxifen treatment in breast cancer
In the following analysis conducted to investigate the
tamoxifen prediction value of CXCL10 and CXCR3, the
Fig. 2 Immunohistochemistry
representations of the different
staining intensities of CXCL10.
All photographs are at 963
magnification, the bar size
represents 20 lm. a No
expression, b weak expression,
c moderate expression, and
d strong expression
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Fig. 3 Immunohistochemistry
representations of the different
staining intensities of CXCR3.
All photographs are at 963
magnification, the bar size
represents 20 lm. a No
expression, b weak expression,
c Moderate expression, and
d Strong expression
Table 1 Correlation of CXCL10 to tumor characteristics
CXCL10 expression P value
- ? ?? ??? n
n (%) n (%) n (%) n (%)
CXCL10 51 (6) 183 (23) 224 (28) 335 (42) 793
Tamoxifen 51 (6) 183 (24) 224 (28) 335 (42) 793 0.54
- 20 (5) 89 (24) 108 (28) 164 (43) 381
? 31 (8) 94 (23) 116 (28) 171 (42) 412
CXCR3 35 (5) 161 (24) 195 (29) 292 (43) 683 0.44
- 5 (22) 5 (22) 1 (4) 12 (52) 23
? 14 (13) 29 (27) 21 (19) 45 (41) 109
?? 9 (3) 59 (22) 71 (27) 124 (47) 263
??? 7 (2) 68 (24) 102 (35) 111 (39) 288
ER-a 10 % 49 (6) 181 (23) 218 (28) 324 (42) 772 0.054
- 13 (8) 43 (25) 49 (28) 67 (39) 172
? 36 (6) 138 (23) 169 (27) 257 (43) 600
PgR 10 % 47 (7) 168 (24) 192 (27) 292 (42) 699 0.44
- 27 (8) 74 (22) 83 (25) 148 (45) 332
? 20 (5) 94 (26) 109 (30) 144 (39) 367
Size 46 (6) 181 (23) 221 (29) 326 (42) 774 0.42
B20 mm 37 (6) 144 (24) 168 (28) 251 (42) 600
[20 mm 9 (5) 37 (21) 53 (30) 75 (43) 174
HER2 48 (7) 174 (24) 205 (28) 309 (42) 736 0.65
- 32 (7) 109 (25) 106 (24) 192 (44) 439
? 7 (5) 27 (20) 42 (31) 61 (45) 137
?? 3 (4) 17 (23) 27 (36) 29 (38) 76
??? 6 (7) 21 (25) 30 (36) 27 (32) 84
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patients with ER-positive tumors were divided in groups
with tumors showing low (no or weak) or high (moderate
or strong) expression. Patients with strong tumoral
CXCL10 expression who received tamoxifen treatment had
significantly improved local recurrence-free survival com-
pared with patients who did not receive tamoxifen [risk
Table 2 Correlation of CXCR3 to tumor characteristics
CXCR3 expression P value
- ? ?? ??? n
n (%) n (%) n (%) n (%)
CXCR3 29 (4) 121 (17) 282 (38) 303 (41) 735
Tamoxifen 29 (4) 121 (17) 280 (38) 301 (41) 731 0.89
– 15 (4) 60 (16) 140 (38) 149 (41) 364
? 14 (4) 61 (17) 140 (38) 152 (41) 367
CXCL10 18 (3) 95 (15) 254 (39) 281 (43) 648 0.44
– 5 (14) 14 (40) 9 (26) 7 (20) 35
? 5 (3) 29 (18) 59 (37) 68 (42) 161
?? 1 (1) 21 (11) 71 (36) 102 (52) 195
??? 12 (4) 45 (15) 124 (43) 111 (38) 292
ER-a 10 % 27 (4) 119 (17) 272 (38) 292 (41) 710 0.67
– 3 (2) 32 (19) 59 (36) 71 (43) 165
? 24 (4) 87 (16) 213 (39) 221 (41) 545
PgR 10 % 25 (4) 105 (16) 249 (38) 273 (42) 652 0.9
– 11 (4) 56 (17) 127 (40) 120 (40) 314
? 14 (4) 49 (15) 122 (36) 153 (45) 338
Size 28 (4) 119 (17) 273 (38) 294 (41) 714 0.45
B20 mm 20 (4) 93 (17) 219 (40) 221 (40) 553
[20 mm 8 (5) 26 (16) 54 (34) 73 (45) 161
HER2 24 (4) 110 (16) 257 (38) 287 (42) 678 \0.001
– 19 (5) 78 (20) 157 (39) 147 (37) 401
? 5 (4) 17 (13) 45 (34) 65 (49) 132
?? 0 (0) 4 (6) 28 (42) 35 (52) 67
??? 0 (0) 11 (14) 27 (35) 40 (51) 78
Fig. 4 Survival curves for tamoxifen-treated patients, grouped
according to tumoral CXCL10 expression in terms of local recur-
rence-free survival. All patient tumors are estrogen receptor positive.
a Patients with moderate/high tumoral CXCL10 expression and
b patients with no/low tumoral CXCL10 expression
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ratio (RR) 0.46 (95 % CI 0.25–0.85, P = 0.01)] (Fig. 4a).
Patients treated with tamoxifen who had low tumoral
expression of CXCL10 showed no significant effect of
treatment on local recurrence-free survival [RR 1.15 (95 %
CI 0.46–2.85, P = 0.77)] (Fig. 4b). No predictive value for
CXCL10 was shown in terms of breast cancer-specific
Fig. 5 Survival curves for tamoxifen-treated patients, grouped
according to tumoral CXCR3 expression. All patient tumors are
estrogen receptor positive. a–c Patients with moderate/high tumoral
CXCR3 expression and d–f patients with no/low tumoral CXCR3
expression. a, d Breast cancer-specific survival. b, e Local recurrence-
free survival. c, f Distant recurrence-free survival
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survival or distant recurrence-free survival (data not
shown).
Patients with strong tumoral CXCR3 expression showed
benefit from tamoxifen treatment with regards to the end
point breast cancer-specific survival [RR 0.34 (95 % CI
0.19–0.62, P \ 0.001)], local recurrence-free survival [RR
0.35 (95 % CI 0.22–0.58, P \ 0.001)], and distant recur-
rence-free survival [RR 0.44 (95 % CI 0.24–0.81,
P = 0.009)] compared with patients who did not receive
tamoxifen treatment (Fig. 5a–c). Patients with tumors that
had low CXCR3 expression showed no significant effect of
tamoxifen treatment for breast cancer-specific survival [RR
1.33 (95 % CI 0.38–4.79, P = 0.65)], local recurrence-free
survival [RR 1.24 (95 % CI 0.41–4.07, P = 0.68)], or
distant recurrence-free survival [RR 1.21 (95 % CI
0.42–3.48, P = 0.72)] (Fig. 5d–f). The interaction test was
significant (P = 0.04) with distant recurrence-free survival
as end point.
CXCR3, but not CXCL10 is a prognostic factor
in breast cancer
In the following analysis, the ability of CXCL10 and
CXCR3 as prognostic factors in tamoxifen untreated
patients was analyzed. Patients were organized in groups
with tumors showing low (no and weak) or high (moderate
or strong) expression. CXCL10 was not a prognostic
marker for breast cancer-specific survival, local recurrence-
free survival, or distant recurrence-free survival. However,
CXCR3 was shown to be a prognostic marker concerning
breast cancer-specific survival [RR 1.48 (95 % CI 1–2.19,
P = 0.05)] (Fig. 6a), and distant recurrence-free survival
[RR 1.40 (95 % CI 1.02–1.92, P = 0.036)] (Fig. 6c).
Multivariate analysis supported this for both breast cancer-
specific survival [RR 1.59 (95 % CI 1–2.53, P = 0.47)]
and distant recurrence-free survival [RR 1.61 (95 % CI
1.09–2.38, P = 0.016)], Table 3. CXCR3 was not a prog-
nostic marker for local recurrence-free survival (Fig. 6b).
Discussion
We report for the first time that patients with ER-positive
tumors and high tumoral CXCL10 expression have a
markedly improved effect of tamoxifen compared with
patients with ER-positive tumors and low tumoral CXCL10
expression in terms of local recurrence-free survival. The
observed improvement of the tamoxifen effect in patients
with high tumoral CXCL10 expression could be a result of
the recruitment of T effector cells to sites of expression [1,
2]. T-cells have been shown to mediate antitumor activity
and protection of the tissue from the recurrence of tumor
cells [2, 20]. In a murine model, Aronica et al. [25] show
that CXCL10 can prevent estrogen-induced tumor forma-
tion and estrogen-induced growth of tumor cells via inhi-
bition of vascular endothelial growth factor (VEGF)
signaling. Taken together with the antiestrogenic properties
of tamoxifen, which results in the inhibition VEGF
Fig. 6 Survival curves for patients who received no endocrine
therapy, grouped according to CXCR3 expression. a Breast cancer-
specific survival, b local recurrence-free survival, and c distant
recurrence-free survival
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signaling, and it is possible that the synergic inhibition of
VEGF by CXCL10 and tamoxifen could give an improved
effect compared with tamoxifen alone [25].
In patients who did not receive endocrine treatment
there was no impact based on CXCL10 expression in terms
of any of our tested endpoints. This could be attributed to
the relatively early stage of breast cancer in our material,
with small tumors and no nodal involvement, thus once the
tumor is removed and the chemotactic recruitment is
weakened, the CXCL10 might no longer be able to predict
patient clinical outcome on its own.
Patients with ER-positive tumors with a high tumoral
CXCR3 expression had improved effect of tamoxifen when
compared with patients with ER-positive tumors and low
CXCR3 expression. CXCR3 cellular membrane expression
is limited to the G2/M phase of the cell cycle [15, 18, 26,
27]. As a result of ER-a inhibition by tamoxifen, the
amount of cells in G2/M phase would likely decrease,
reducing CXCR3-mediated signaling. Indeed, Janis et al.
found that CXCR3 levels decreased following tamoxifen
stimulation [28]. Thus, tumor cells dependent on CXCR3
signaling for directing migration, metastasis, or prolifera-
tion would find themselves bereft of both ER-a signaling
and CXCR3 signaling.
We report that high CXCR3 expression is a good
indicator of tamoxifen response, while in patients who
receive no endocrine treatment high tumoral CXCR3
expression was associated with a worse patient outcome.
The significant impact of high CXCR3 expression in
relation to prognosis of patient outcome was seen for
distant recurrence-free survival, which may be attributed
to the ability of CXCR3 to mediate metastasis, shown in
several other forms of cancer [10, 15–17, 29–31]. Our
prognostic data from CXCR3 in breast cancer are sup-
ported by Ma et al. [16], who showed that high CXCR3
expression levels are associated with a worsened prog-
nosis. The patient material used by Ma et al. is small, but
interestingly, they found the correlation between CXCR3
level and patient outcome only in the subset of patients
which, like our patients, have no nodal involvement,
indicating that CXCR3 might be an important aspect of
early metastasis. No combination of the expressions of
CXCR3 and CXCL10 provides any insight into patient
prognosis (data not shown), a result in line with obser-
vations in a previous study by Mulligan et al. [32]. These
data taken together with the clinical importance of distant
recurrence in terms of patient point toward a role of
CXCR3, but not CXCL10 in prognosis of patient out-
come, in terms of metastatic potential and overall
survival.
We found no correlation between CXCL10 and CXCR3
levels, which contradicts previous findings by Mulligan
et al. This difference could be attributed to differences in
the materials. Our material is selected from low stage
cancers, while Mulligan used heterogeneous material with
varying stage, nodal involvement and grade, in addition
over a hundred of these patients had mutations in either
BRCA1 or BRCA2 [32]. We found a correlation between
HER2 and CXCR3 expression. Nejatollahi et al. describe
that after treatment with single chain fragment variable
antibodies targeting HER2, the protein levels of both HER2
and CXCR3 were reduced [33].
CXCR3 has two primary CXCL10-binding isoforms
reported in the literature, CXCR3-A and CXCR3-B. Sev-
eral claims have been made to CXCR3-A- and CXCR3-B-
specific effects, with CXCR3-A-supporting proliferative
migratory effects and CXCR3-B-antiproliferative and an-
timigratory effects [15–18]. However, due to a large
degree of homology between the two proteins, with
CXCR3-B having a 47 amino acid insert as the only area
of dissimilarity to CXCR3-A [17], there are no publicly
available antibodies which are subtype specific. Similar
problems are present utilizing mRNA quantification with
qPCR, since the region surrounding the area of dissimi-
larity is poorly suited for primers or probes, and no
reported [17, 18, 34, 35] or commercially available primer/
probe set can reliably and with good efficiency quantify
mRNA from CXCR3-A and not include false positives
from CXCR3-B mRNA.
Table 3 Multivariate analysis of CXCR3 prognostic factors in
patients not treated with tamoxifen
Marker P-value Risk ratio
Breast cancer survival
CXCR3 0.048494 1.59 95 % CI (12.52)
CXCL10 0.807265 0.96 95 % CI (0.72–1.29)
ER 10 % 0.231437 0.65 95 % CI (0.32–1.32)
Pgr 10 % 0.498511 1.27 95 % CI (0.64–2.51)
HER2 0.224406 1.59 95 % CI (0.75–3.33)
Size \20 mm 0.000161 2.85 95 % CI (1.66–4.91)
Local recurrence-free survival
CXCR3 0.29 1.29 95 % CI (0.8–2.07)
CXCL10 0.35 1.21 95 % CI (0.81–1.79)
ER 10 % 0.31 0.59 95 % CI (0.22–1.63)
Pgr 10 % 0.1 2.13 95 % CI (0.86–5.28)
HER2 0.73 1.22 95 % CI (0.39–3.83)
Size \20 mm 0.57 0.78 95 % CI (0.34–1.81)
Distant metastasis
CXCR3 0.017 1.61 95 % CI (1.09–2.38)
CXCL10 0.49 0.91 95 % CI (0.71–1.17)
ER 10 % 0.15 0.61 95 % CI (0.32–1.18)
Pgr 10 % 0.048 1.85 95 % CI (1.01–3.42)
HER2 0.15 1.65 95 % CI (0.83–3.27)
Size \20 mm 0.00031 2.41 95 % CI (1.49–3.89)
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Conclusion
Herein, we show that in ER-positive patients both the
chemokine CXCL10 and its primary receptor CXCR3 can
be used to predict improved patient treatment response to
tamoxifen compared to when only ER is used as a clinical
marker. We propose that this pathway be further evaluated
for the use in clinical setting to clearly define the role these
markers have in the outcome of the patient in different
patient subsets, and whether treatment targeting the
CXCL10/CXCR3 axis could provide further benefit to
these patients. We also found that CXCR3 status can be a
prognostic tool in predicting metastasis, as well as reduced
overall survival.
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